Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen R&D Ireland
ClinicalTrials.gov Identifier:
NCT01571570
First received: January 23, 2012
Last updated: June 24, 2013
Last verified: June 2013

January 23, 2012
June 24, 2013
March 2012
May 2012   (final data collection date for primary outcome measure)
  • Comparing the bioavailability of oral solution and oral suspension formulation with the capsule formulation of TMC435 (fed state) [ Time Frame: 4 days ] [ Designated as safety issue: No ]
    Comparing the rate and extent of absorption (bioavailability) of 2 different liquid formulations (oral suspension [150 mg ie, 20 mg/mL] and oral solution [150 mg ie, 10 mg/mL]) versus capsule formulation (150 mg) of TMC435, after a high-fat breakfast (fed state)
  • Comparing the bioavailability of oral solution and oral suspension formulation of TMC435 in fed and fasted state [ Time Frame: 4 days ] [ Designated as safety issue: No ]
    Comparing the rate and extent of absorption (bioavailability) of 2 different liquid formulations (oral suspension [150 mg ie, 20 mg/mL] and oral solution [150 mg ie, 10 mg/mL]) of TMC435 in fed state (high-fat breakfast) versus fasted state
  • Comparing the bioavailability of concept K capsule and concept L capsule formulation with the capsule formulation of TMC435 (fed state) [ Time Frame: 4 days ] [ Designated as safety issue: No ]
    Comparing the rate and extent of absorption (bioavailability) of 2 different capsule formulations (concept K capsule [150 mg] and concept L capsule [150 mg]) versus capsule formulation (150 mg) of TMC435 after a high-fat breakfast (fed state)
Same as current
Complete list of historical versions of study NCT01571570 on ClinicalTrials.gov Archive Site
  • Number of participants with adverse events [ Time Frame: 18 days ] [ Designated as safety issue: Yes ]
    Adverse events, abnormal clinical laboratory findings, abnormalities assessed in vital signs examination, physical examination, ECG measurements were evaluated for safety and tolerability during the study
  • Acceptability of taste assessed by taste questionnaires [ Time Frame: Day 1 of Treatment B and E ] [ Designated as safety issue: No ]
    Taste Questionnaires used to assess taste acceptability of oral suspension and solution of TMC435 under fasted conditions. Taste Questionnaire for adults: participant had to select appropriate choice (None, Weak, Moderate, Strong) for 3 different types of tastes "Sweetness, Bitterness, Flavour" and also select appropriate choice (Bad, Amost acceptable, Acceptable and Good) for the Overall taste. For pediatric participants: fill the visual analog scale by selecting appropriate choice (Dislike it very much, Dislike it a little, Not sure, Like it a little and Like it very much)
Same as current
Not Provided
Not Provided
 
A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.
A Phase I, Open-Label, Randomized, 3-Panel, 3-way Crossover Trial in Healthy Adult Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of 2 Liquid Formulations or 2 Different Capsule Concept Formulations Compared ot the Phase III 150 mg Capsule, and to Assess the Effect of Food on the Bioavailability of TMC435 Following Administration of the Liquid Formulations.

The purpose of this study is to evaluate the relative bioavailability and the short-term safety and tolerability of TMC435 following administration of 3 single oral doses of 150 mg, given as different formulations in healthy adult participants. In addition, this study is to assess for the acceptability of the taste of both liquid formulations.

TMC435 is being investigated for the treatment of chronic hepatitis C infection. The current study is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (study medication is assigned by chance) study designed to assess the relative bioavailability and food effect of 2 liquid formulations of TMC435, currently being developed for potential pediatric use, compared to the Phase III 150 mg capsule. Also new capsule concept formulations will be investigated in comparison with the Phase III 150 mg capsule. The study will be performed in healthy adult participants and is divided over 3 panels. Participants will be randomized within a panel. Each participant will receive 3 different treatments according to a classical 6-sequence, 3-period Williams design. In Panel 1 and Panel 2, a single oral dose of 150 mg TMC435 oral suspension respectively with other strength will be compared with the capsule used in Phase III. In Panel 3, two different capsule concept formulations will be compared with the capsule used in Phase III. In panels containing the liquids, formulations will be compared under fasted and fed conditions to investigate the food effect. In all treatments, the participants will receive medication on Day 1 of each treatment. There will be a washout period of at least 7 days between subsequent treatments. The main focus of the trial is the pharmacokinetic characteristics of all formulations (level-profile of TMC435 over time in the blood stream). This evaluation requires multiple blood samples from Day 1 till Day 4 in each treatment. Safety assessments (blood and urine tests, blood pressure, pulse, electrocardiogram, and physical examination) will follow a different schedule and will be evaluated from signing of the Informed Consent Form onwards until the last trial-related visit throughout the study.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy Volunteers
  • Drug: TMC435 150 mg capsule
    single oral dose of 150 mg TMC435 150 mg capsule
    Other Name: TMC435
  • Drug: TMC435 150 mg oral suspension (20 mg/mL)
    single oral dose of 150 mg TMC435 oral suspension
    Other Name: TMC435
  • Drug: TMC435 150 mg oral solution (10 mg/mL)
    single oral dose of 150 mg TMC435 oral solution
    Other Name: TMC435
  • Drug: TMC435 150 mg capsule concept K
    single oral dose of 150 mg TMC435 capsule concept K
    Other Name: TMC435
  • Drug: TMC435 150 mg capsule concept L
    single oral dose of 150 mg TMC435 capsule concept L
    Other Name: TMC435
  • Experimental: Treatment A
    Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
    Intervention: Drug: TMC435 150 mg capsule
  • Experimental: Treatment B
    Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
    Intervention: Drug: TMC435 150 mg oral suspension (20 mg/mL)
  • Experimental: Treatment C
    Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
    Intervention: Drug: TMC435 150 mg oral suspension (20 mg/mL)
  • Experimental: Treatment D
    Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
    Intervention: Drug: TMC435 150 mg capsule
  • Experimental: Treatment E
    Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
    Intervention: Drug: TMC435 150 mg oral solution (10 mg/mL)
  • Experimental: Treatment F
    Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
    Intervention: Drug: TMC435 150 mg oral solution (10 mg/mL)
  • Experimental: Treatment G
    Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
    Intervention: Drug: TMC435 150 mg capsule
  • Experimental: Treatment H
    Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
    Intervention: Drug: TMC435 150 mg capsule concept K
  • Experimental: Treatment I
    Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
    Intervention: Drug: TMC435 150 mg capsule concept L
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers should be healthy on the basis of physical examination, medical history, laboratory tests, 12-lead electrocardiogram and vital signs, performed at screening, have a body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included and be non-smoking for at least 3 months prior to screening.
  • Women must be postmenopausal for at least 2 years and/or surgically sterile or not heterosexually active for duration of the trial.

Exclusion Criteria:

  • All participants with known allergies, hypersensitivity or intolerance to TMC435 or any of the excipients.
  • Use of concomitant medication, including over the counter products, herbal medication and dietary supplements, except for paracetamol (acetaminophen) or ibuprofen.
  • Any condition that, in the opinion of the investigator, would compromise the study or well-being of the participant or prevent the subject from meeting or performing study requirements.
  • History or suspicion of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in investigator's opinion would compromise participant's safety and/or compliance with the trial procedures.
  • Participation in an investigational drug trial with TMC435.
  • Infected with HIV or Hepatitic A, B or C.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01571570
CR100787, TMC435HPC1002
No
Janssen R&D Ireland
Janssen R&D Ireland
Not Provided
Study Director: Janssen R&D Ireland Clinical Trial Janssen R&D Ireland
Janssen R&D Ireland
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP